PCOC: Patient-Centered Oncology Care

Mary Caffrey, executive editor of AJMC, interviews Patty and Brian Koffman, MDCM, on why caregivers are critical to outpatient CAR T-cell therapy and bispecific antibody access.

Leaders from Boehringer Ingelheim, Incyte, Pfizer, and Takeda told the audience at Patient-Centered Oncology Care® that artificial intelligence (AI) is compressing discovery timelines, but that gaps in testing, data, and community access still decide which patients benefit.

As National Family Caregivers Month begins, AJMC presents coverage from PCOC's first-ever panel on caregiving, where participants discuss demands on family members who are the “eyes and ears” when patients receive CAR T, bispecific, or transplant treatments.

Cleveland Clinic's Beth Faiman, PhD, MSN, says fast-moving myeloma care requires funded education and fewer barriers for advanced practitioner-led care.

Seven oncology leaders at PCOC in Nashville share what patient-centered care means today and how they want it to change over the next 5 years.

OneOncology's Larry Bilbrey outlines network-level contracting, data security, physician review of AI output, and clear vendor lanes for AI.

OneOncology's Edward "Ted" Arrowsmith, MD, MPH, explains how pathways keep pace with new approvals and why real-time data will shape their future.

Tennessee Oncology's Wade Iams, MD, MSCI, discusses staffing and tocilizumab access as barriers to expanding BiTE therapy and the costs of cell therapy.

OneOncology's Larry Bilbrey explains how to guide practices on AI without endorsing products and why technology gaps outweigh workflow problems.

COA's Nicolas Ferreyros discusses next steps for PBM reform, funding for supportive cancer services, and a hopeful outlook for community oncology.

AI, patient voice in pathways, and caregiver support are shaping community oncology, AON leaders said at Patient-Centered Oncology Care.

Cleveland Clinic's Beth Faiman, PhD, MSN, discusses advanced practitioners' reimbursement and how outpatient trispecific antibodies could increase access.

Tennessee Oncology’s Johnetta Blakely, MD, MS, explains why physicians must review high-stakes AI-assisted orders and how patients view AI in oncology.

OneOncology's Edward "Ted" Arrowsmith, MD, MPH, explains why cost stays out of its pathway process and how point-of-care ordering puts pathways to work.

Tennessee Oncology's Wade Iams, MD, MSCI, discusses insured patients' out-of-pocket costs, platinum shortages, and access to CAR T and BiTE therapies.

Nicolas Ferreyros, of COA, warns IRA drug price negotiation threatens community oncology payments and urges Part B, 340B, and insurer reforms.

Cathy Eng, MD, says flat funding for NCI-sponsored trials discourages site participation and slows data, despite their importance.

Alyssa Schatz, DrPH, MSW, of NCCN, explains how insurance shifts and drug shortages threaten access to cancer care.

OneOncology's Larry Bilbrey discusses why unstructured data limits artificial intelligence and how practices can weigh AI purchases by their payoff.

COA's Nicolas Ferreyros discusses real-world survival data for community oncology, health system consolidation, and barriers to CAR T-cell access.

Cathy Eng, MD, discusses a BREAKWATER post hoc analysis showing poorer survival in early-onset BRAF V600E colorectal cancer.

Cleveland Clinic's Beth Faiman, PhD, MSN, discusses AP-led clinics, managing talquetamab taste changes, and infection prophylaxis with bispecifics.

OneOncology's Edward "Ted" Arrowsmith, MD, MPH, explains how patient-reported outcomes and national disease groups can make cancer pathways more dynamic.

Panelists ask whether cancer care will shift toward home-administered infusions as payers push for change. Other topics in this forward-looking session include new delivery tech and practice-led solutions.

Mitchell Blewett, PharmD, MS, of Cleveland Clinic, explains why formulary approval is only the midpoint before a new oncology drug reaches patients.

Cathy Eng, MD, explains how young adults with cancer face career, fertility, and body image concerns as well as where to find support.

AI, patient voice in pathways, and caregiver support are shaping community oncology, AON leaders said at Patient-Centered Oncology Care.

Cathy Eng, MD, FACP, FASCO, says young patients with colorectal cancer often look healthy and present at stage IV, making symptom awareness critical.

Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.

Mayo Clinic's Scott Soefje, PharmD, MBA, explains how logistics, contracts, and cost shape access to new cancer drugs and high-cost drug reviews.